Cytrellis Biosystems Advances Skin Rejuvenation with FDA-Cleared Ellacor System and $50M Series C Funding

Cytrellis Biosystems, a Boston-based company specializing in skin rejuvenation technologies (hereinafter referred to as “Cytrellis”), has recently enjoyed a period of remarkable success. In July, the U.S. Food and Drug Administration (FDA) approved its first proprietary product, the ellacor® System utilizing Micro-Coring™ technology, providing strong support and a clear pathway for its initial commercial launch. Subsequently, in September, the company announced the closure of a $50 million Series C financing round. To date, Cytrellis has raised a total of $86.1 million in funding.

This round of financing was led by D1 Capital Partners, with participation from existing institutional investors ARCH Venture Partners and PFM Health Sciences, as well as new investor Sands Capital. The funds will be used to develop Cytrellis’ commercial infrastructure and support additional clinical studies, product development, and manufacturing.

It is worth noting that ARCH Venture Partners has participated in every funding round since Cytrellis’s Series A, investing for three consecutive rounds. What makes Cytrellis so compelling that it has secured the continued support of a top-tier venture capital firm like ARCH Venture Partners?

Cytrellis’ leadership team has decades of experience in the development and commercialization of medical devices.

Current Leadership Structure

Although the company’s leadership team has changed over time, its “soul figures,” Karen Cronholm and Diane Marcou, remain.

Karen Cronholm is the CEO of Cytrellis, with over 25 years of experience in the life sciences and medical device industries. At Cynosure, she directed marketing and product management for multiple aesthetic product lines used to treat cellulite and reduce fat. She established an operations team that enhanced company efficiency, launched multiple products, and generated significant value for the organization. Previously, she served as Marketing Director for the Laboratory Solutions business at EMD Millipore. During her 12-year tenure at EMD Millipore, she successfully developed numerous new technologies and held various roles, including Marketing Manager, R&D Scientist, and Quality Manager. Karen holds a Ph.D. in Microbiology from the University of New Hampshire and an MBA from Northeastern University.

Diane Marcou currently serves as the CFO of Cytrellis. She has provided financial and strategic consulting services to numerous life sciences companies, including Fractyl Laboratories Inc., T2 Biosystems, TARIS Biomedical, ByAllAccounts, Inc., Ivenix, and Topera Medical. With over 20 years of experience working in both private and public sector organizations, she has repeatedly assisted companies in securing recognition from investment institutions and possesses extensive expertise in managing investor relations. Diane is a Certified Public Accountant (CPA), having qualified at PwC (formerly Coopers & Lybrand), and holds a Bachelor of Science in Business Administration from Boston College.

Karen and Diane, like captain and helmsman, have steered the “Cynosure” through wind and waves since the company’s inception.

Traditional photoelectric methods can repair damaged skin, but their efficacy is limited or they require prolonged healing times, and they do not necessarily significantly reduce or eliminate skin laxity. Patients must undergo surgery to remove excess skin and mitigate sagging; however, this technique carries medical safety risks such as scarring and complications, influenced by factors including the physician’s technical proficiency and the patient’s physical constitution.

Cytrellis’s product technology mitigates the aforementioned risks. Cytrellis’s first product, Ellacor—which has recently received approval from the U.S. FDA—is a novel, proprietary system utilizing Micro-Coring® technology. By employing micro-excision of the skin, it pioneers a new approach to dermatological treatment beyond energy-based devices and surgical interventions. This technology is not based on traditional energy-based therapies.

This treatmentNo surgery, no scarring, rapid results, with obvious and natural effects, and because no thermal energy is used during the treatment, thereforeHealing is typically faster than with energy-based devices.. Used by healthcare professionals to treat individuals aged 22 years or olderFitzpatrick Skin Types I–IVmoderate to severe wrinkles in the lower face of adults.

Fitzpatrick Pathank Sun-Reactive Skin Type

VCBeat Graphic

Ellacor includes a handheld device and consumables, usingGentle Method for Precise Treatment of Large-Area Skin, the device also includes a skin coring mechanism, which is an energy-free needle-based tool that mechanically extracts microscopic columns of skin, each less than half a millimeter in diameter. These needles create micro-channels upon penetration into the skin, which then converge and heal, triggering the collagen remodeling phase to achieve a tightening effect. Moreover, operators can tailor the treatment according to user needs,Precise control over the position and depth of micro-incisions.

Doctor Operating Scenario. Image source: Instagram

According to data from Cytrellis’s official website, 80 participants showed favorable skin tissue healing 90 days after undergoing this minimally invasive procedure. The pain level during treatment was rated at 0.36, comparable to a mosquito bite, indicating very mild discomfort. Overall satisfaction with the improvement reached 93%.

Clinical Outcomes at 90 Days Post-Cytrellis Treatment. Image source: Cytrellis video footage.

Ellacor has numerous advantages.From a safety perspective, no surgery, no scarring, and higher safety;From a technical operational perspective, which requires operation by professional medical personnel, but the procedure is relatively simple and applicable to a wide range of scenarios;From a User Experience Perspective, without concerns about surgical risks, leading to higher patient acceptance; it delivers rapid and noticeable results with a short recovery period, minimizing disruption to patients' work and daily life; the aesthetic outcome appears more natural; it helps avoid laser-related complications such as scarring, hyperpigmentation, and blistering, while also allowing customization based on individual patient needs.Targeted ImprovementSagging skin due to aging on the face or other parts of the body.

New York dermatologist Doris Day even stated, “If you start using Ellacor for maintenance in your youth, you will save a significant amount on cosmetic procedures later in life.” It must be said that such a perspective holds immense appeal for those seeking to preserve their beauty.

But we must also look at the other side of the coin. First, Cytrellis’sThe product portfolio is relatively limited., currently only Ellacor, which appears somewhat monotonous compared to the dazzling product lines of other medical aesthetic device companies,The functionality is also somewhat limited.. However, from another perspective, “one centimeter wide, ten thousand meters deep”—focusing on honing expertise in a single domain—may well be the reason Cytrellis has attracted investor favor.

Secondly, Ellacor thisThe product is still too new., and its potential issues and risks can only be verified over time and through further practice.

Finally, although Ellacor delivers excellent results,Cannot Replace Cosmetic Surgery, because this technique acts only on the skin; in addition to excising excess skin, it aims to lift and reposition ptotic muscle tissue, but it cannot adjust or repair facial muscles or fascia.

Cytrellis rarely engages in public promotion, yet it is easy to discern from its financing history the substantial financial commitment and support from investors, as well as the endorsement by new capital. Judging by its fundraising pace, Cytrellis completes a round of financing every three years, advancing at a steady clip—a testament to the power of quiet, deep currents.

Even the finest wine fears a deep alley. While strengthening its core capabilities and refining its products, Cytrellis has also sought greater external visibility over the past two years, gaining prominence in major competitions to lay the groundwork for future commercialization. In 2020, Cytrellis participated in the “Innovation Shark Tank” competition during the IMCAS World Congress, where it was named the IMCAS Innovation of the Year Runner-up and received the IMCAS 2020 Innovation Potential Award. In 2021, Cytrellis was nominated as a finalist in the prestigious Terra2 Solutions Skin Health Innovation Competition.

Ellacor’s FDA approval this July has provided strong support for its inaugural commercial launch.

At present, the company’s products have not yet been deployed at scale; its job openings are primarily for technical research and sales roles, closely centered aroundProductandSalesends. According to Cytrellis, the company plans to collaborate with key opinion leaders in the industry and expects to launch fully in 2022. VCBeat will continue to monitor Cytrellis’s developments.